

Provisional Peer-Reviewed Toxicity Values for  
  
Lactonitrile  
(CASRN 78-97-7)

Superfund Health Risk Technical Support Center  
National Center for Environmental Assessment  
Office of Research and Development  
U.S. Environmental Protection Agency  
Cincinnati, OH 45268

## **AUTHORS, CONTRIBUTORS, AND REVIEWERS**

### **CHEMICAL MANAGER**

Chris Cubbison, PhD  
National Center for Environmental Assessment, Cincinnati, OH

### **DRAFT DOCUMENT PREPARED BY**

SRC, Inc.  
7502 Round Pond Road  
North Syracuse, NY 13212

### **PRIMARY INTERNAL REVIEWERS**

Elizabeth Owens, PhD  
National Center for Environmental Assessment, Cincinnati, OH

Jeff Swartout  
National Center for Environmental Assessment, Cincinnati, OH

This document was externally peer reviewed under contract to:

Eastern Research Group, Inc.  
110 Hartwell Avenue  
Lexington, MA 02421-3136

Questions regarding the content of this PPRTV assessment should be directed to the EPA Office of Research and Development's National Center for Environmental Assessment, Superfund Health Risk Technical Support Center (513-569-7300).

## TABLE OF CONTENTS

COMMONLY USED ABBREVIATIONS AND ACRONYMS.....	iv
BACKGROUND .....	1
DISCLAIMERS.....	1
QUESTIONS REGARDING PPRTVs.....	1
INTRODUCTION .....	2
REVIEW OF POTENTIALLY RELEVANT DATA (NONCANCER AND CANCER).....	5
HUMAN STUDIES .....	8
ANIMAL STUDIES .....	8
Oral Exposures.....	8
Inhalation Exposures.....	9
OTHER DATA (SHORT-TERM TESTS, OTHER EXAMINATIONS) .....	10
Acute Toxicity .....	10
Genotoxicity.....	10
DERIVATION OF PROVISIONAL VALUES .....	12
DERIVATION OF ORAL REFERENCE DOSES .....	12
DERIVATION OF INHALATION REFERENCE CONCENTRATIONS.....	13
CANCER WEIGHT-OF-EVIDENCE DESCRIPTOR .....	13
DERIVATION OF PROVISIONAL CANCER POTENCY VALUES.....	13
APPENDIX A. SCREENING PROVISIONAL VALUES .....	14
APPENDIX B. DATA TABLES.....	19
APPENDIX C. BENCHMARK DOSE MODELING RESULTS .....	23
APPENDIX D. REFERENCES.....	41

## COMMONLY USED ABBREVIATIONS AND ACRONYMS<sup>1</sup>

$\alpha$ 2u-g	alpha 2u-globulin	MN	micronuclei
ACGIH	American Conference of Governmental Industrial Hygienists	MNPCE	micronucleated polychromatic erythrocyte
AIC	Akaike's information criterion	MOA	mode of action
ALD	approximate lethal dosage	MTD	maximum tolerated dose
ALT	alanine aminotransferase	NAG	<i>N</i> -acetyl- $\beta$ -D-glucosaminidase
AR	androgen receptor	NCEA	National Center for Environmental Assessment
AST	aspartate aminotransferase	NCI	National Cancer Institute
atm	atmosphere	NOAEL	no-observed-adverse-effect level
ATSDR	Agency for Toxic Substances and Disease Registry	NTP	National Toxicology Program
BMD	benchmark dose	NZW	New Zealand White (rabbit breed)
BMDL	benchmark dose lower confidence limit	OCT	ornithine carbamoyl transferase
BMDS	Benchmark Dose Software	ORD	Office of Research and Development
BMR	benchmark response	PBPK	physiologically based pharmacokinetic
BUN	blood urea nitrogen	PCNA	proliferating cell nuclear antigen
BW	body weight	PND	postnatal day
CA	chromosomal aberration	POD	point of departure
CAS	Chemical Abstracts Service	POD <sub>ADJ</sub>	duration-adjusted POD
CASRN	Chemical Abstracts Service registry number	QSAR	quantitative structure-activity relationship
CBI	covalent binding index	RBC	red blood cell
CHO	Chinese hamster ovary (cell line cells)	RDS	replicative DNA synthesis
CL	confidence limit	RfC	inhalation reference concentration
CNS	central nervous system	RfD	oral reference dose
CPN	chronic progressive nephropathy	RGDR	regional gas dose ratio
CYP450	cytochrome P450	RNA	ribonucleic acid
DAF	dosimetric adjustment factor	SAR	structure activity relationship
DEN	diethylnitrosamine	SCE	sister chromatid exchange
DMSO	dimethylsulfoxide	SD	standard deviation
DNA	deoxyribonucleic acid	SDH	sorbitol dehydrogenase
EPA	Environmental Protection Agency	SE	standard error
ER	estrogen receptor	SGOT	serum glutamic oxaloacetic transaminase, also known as AST
FDA	Food and Drug Administration	SGPT	serum glutamic pyruvic transaminase, also known as ALT
FEV <sub>1</sub>	forced expiratory volume of 1 second	SSD	systemic scleroderma
GD	gestation day	TCA	trichloroacetic acid
GDH	glutamate dehydrogenase	TCE	trichloroethylene
GGT	$\gamma$ -glutamyl transferase	TWA	time-weighted average
GSH	glutathione	UF	uncertainty factor
GST	glutathione-S-transferase	UF <sub>A</sub>	interspecies uncertainty factor
Hb/g-A	animal blood-gas partition coefficient	UF <sub>C</sub>	composite uncertainty factor
Hb/g-H	human blood-gas partition coefficient	UF <sub>D</sub>	database uncertainty factor
HEC	human equivalent concentration	UF <sub>H</sub>	intraspecies uncertainty factor
HED	human equivalent dose	UF <sub>L</sub>	LOAEL-to-NOAEL uncertainty factor
i.p.	intraperitoneal	UF <sub>S</sub>	subchronic-to-chronic uncertainty factor
IRIS	Integrated Risk Information System	U.S.	United States of America
IVF	in vitro fertilization	WBC	white blood cell
LC <sub>50</sub>	median lethal concentration		
LD <sub>50</sub>	median lethal dose		
LOAEL	lowest-observed-adverse-effect level		

<sup>1</sup>Abbreviations and acronyms not listed on this page are defined upon first use in the PPRTV document.

## **PROVISIONAL PEER-REVIEWED TOXICITY VALUES FOR LACTONITRILE (CASRN 78-97-7)**

### **BACKGROUND**

A Provisional Peer-Reviewed Toxicity Value (PPRTV) is defined as a toxicity value derived for use in the Superfund Program. PPRTVs are derived after a review of the relevant scientific literature using established Agency guidance on human health toxicity value derivations. All PPRTV assessments receive internal review by at least two National Center for Environment Assessment (NCEA) scientists and an independent external peer review by at least three scientific experts.

The purpose of this document is to provide support for the hazard and dose-response assessment pertaining to chronic and subchronic exposures to substances of concern, to present the major conclusions reached in the hazard identification and derivation of the PPRTVs, and to characterize the overall confidence in these conclusions and toxicity values. It is not intended to be a comprehensive treatise on the chemical or toxicological nature of this substance.

PPRTV assessments are eligible to be updated on a 5-year cycle to incorporate new data or methodologies that might impact the toxicity values or characterization of potential for adverse human-health effects and are revised as appropriate. Questions regarding nomination of chemicals for update can be sent to the appropriate U.S. Environmental Protection Agency (EPA) Superfund and Technology Liaison (<https://www.epa.gov/research/fact-sheets-regional-science>).

### **DISCLAIMERS**

The PPRTV document provides toxicity values and information about the adverse effects of the chemical and the evidence on which the value is based, including the strengths and limitations of the data. All users are advised to review the information provided in this document to ensure that the PPRTV used is appropriate for the types of exposures and circumstances at the site in question and the risk management decision that would be supported by the risk assessment.

Other U.S. EPA programs or external parties who may choose to use PPRTVs are advised that Superfund resources will not generally be used to respond to challenges, if any, of PPRTVs used in a context outside of the Superfund program.

This document has been reviewed in accordance with U.S. EPA policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.


### **QUESTIONS REGARDING PPRTVs**

Questions regarding the content of this PPRTV assessment should be directed to the EPA Office of Research and Development's (ORD's) NCEA, Superfund Health Risk Technical Support Center (513-569-7300).

## INTRODUCTION

Lactonitrile, CASRN 78-97-7, belongs to a class of compounds known as cyanohydrins. It is used mainly as a solvent and as an intermediate in the manufacture of lactic acid and its derivatives, such as ethyl lactate ([Lewis and Hawley, 2007](#); [Cholod, 2001](#)). Lactonitrile is listed on EPA's Toxic Substances Control Act (TSCA) public inventory ([U.S. EPA, 2015a](#)), is registered with Europe's Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) program ([ECHA, 2017](#)), and was assessed under the EPA's High Production Volume (HPV)/Organisation for Economic Co-operation and Development (OECD) Screening Information Data Set (SIDS) Programme ([OECD, 2004](#)). Lactonitrile is listed as an EPA Extremely Hazardous Substance (S302) and has been assigned a Threshold Planning Quantity of 1,000 pounds ([U.S. EPA, 2015b](#)).

The empirical formula for lactonitrile is  $C_3H_5NO$ , and its structure is shown in Figure 1. Synonyms for lactonitrile include the following: laktonitrile, lactonitrite, 2-hydroxypropanenitrile, and 2-hydroxypropionitrile. Commercial production of lactonitrile occurs by the base-catalyzed reaction of equimolar amounts of acetaldehyde and hydrogen cyanide in the presence of 1.5 of 20% sodium hydroxide ([Cholod, 2001](#)). Table 1 summarizes the physicochemical properties of lactonitrile. Lactonitrile is a straw-yellow liquid at room temperature. It is unstable at high pH and will undergo acid hydrolysis to form propanoic acid ([Cholod, 2001](#)). The hydrolysis half-life for lactonitrile was reported as 15 days at pH 9 and 25°C; however, it was not hydrolyzed at pH 4 or 7 ([ECHA, 2017](#)). Lactonitrile's vapor pressure indicates that it will exist almost entirely as a vapor in the atmosphere. The estimated half-life of vapor-phase lactonitrile in air by reaction with photochemically produced hydroxyl radicals is 6.7 days. The moderate vapor pressure and Henry's law constant for lactonitrile indicate that it may volatilize from either dry or moist surfaces. The estimated high water solubility and low soil adsorption coefficient for lactonitrile indicate that the compound may leach to groundwater or undergo runoff after a rain event. Based on screening tests, lactonitrile may also undergo ready biodegradation in the environment ([ECHA, 2017](#)).



**Figure 1. Lactonitrile Structure**

Table 1. Physicochemical Properties of Lactonitrile (CASRN 78-97-7)	
Property (unit)	Value
Physical state	Liquid
Boiling point (°C)	160.96 <sup>a</sup>
Melting point (°C)	-40 <sup>a</sup>
Density (g/cm <sup>3</sup> at 20°C)	0.9877 <sup>b</sup>
Vapor pressure (mm Hg at 25°C)	0.119 <sup>a</sup>
pH (unitless)	NA
pKa (unitless)	NA
Solubility in water (mg/L at 25°C)	4.66 × 10 <sup>5</sup> <sup>a</sup>
Octanol-water partition coefficient (log K <sub>ow</sub> )	-0.94 <sup>a</sup>
Henry's law constant (atm-m <sup>3</sup> /mol at 25°C)	9.8 × 10 <sup>-6</sup> (estimated) <sup>a</sup>
Soil adsorption coefficient K <sub>oc</sub> (L/kg)	1 (estimated) <sup>a</sup>
Atmospheric OH rate constant (cm <sup>3</sup> /molecule-sec at 25°C)	1.6 × 10 <sup>-12</sup> (estimated) <sup>a</sup>
Atmospheric half-life (d)	6.7 (estimated) <sup>a</sup>
Relative vapor density (air = 1)	2.45 <sup>c</sup>
Molecular weight (g/mol)	71 <sup>a</sup>
Flash point (closed cup in °C)	77 <sup>c</sup>

<sup>a</sup>U.S. EPA (2012c).

<sup>b</sup>Lide (2008).

<sup>c</sup>Lewis (2012).

NA = not applicable.

A summary of available toxicity values for lactonitrile from EPA and other agencies/organizations is provided in Table 2.

<b>Table 2. Summary of Available Toxicity Values for Lactonitrile (CASRN 78-97-7)</b>			
<b>Source (parameter)<sup>a, b</sup></b>	<b>Value (applicability)</b>	<b>Notes</b>	<b>Reference(s)</b>
<b>Noncancer</b>			
IRIS	NV	NA	<a href="#">U.S. EPA (2017)</a>
HEAST	NV	NA	<a href="#">U.S. EPA (2011a)</a>
DWSHA	NV	NA	<a href="#">U.S. EPA (2012a)</a>
ATSDR	NV	NA	<a href="#">ATSDR (2017)</a>
IPCS	NV	NA	<a href="#">IPCS (2017)</a> ; <a href="#">WHO (2017)</a>
Cal/EPA	NV	NA	<a href="#">Cal/EPA (2014)</a> ; <a href="#">Cal/EPA (2017a)</a> ; <a href="#">Cal/EPA (2017b)</a>
OSHA	NV	NA	<a href="#">OSHA (2006)</a> ; <a href="#">OSHA (2011)</a>
NIOSH	NV	NA	<a href="#">NIOSH (2016)</a>
ACGIH	NV	NA	<a href="#">ACGIH (2016)</a>
DOE (PAC)	PAC-1: 0.24 mg/m <sup>3</sup> ; PAC-2: 2.6 mg/m <sup>3</sup> ; PAC-3: 16 mg/m <sup>3</sup>	Based on TEEL values	<a href="#">DOE (2015)</a>
USAPHC (air-MEG)	1-hr critical: 150 mg/m <sup>3</sup> ; 1-hr marginal: 18 mg/m <sup>3</sup> ; 1-hr negligible: 10 mg/m <sup>3</sup>	Based on TEEL values	<a href="#">U.S. APHC (2013)</a>
<b>Cancer</b>			
IRIS	NV	NA	<a href="#">U.S. EPA (2017)</a>
HEAST	NV	NA	<a href="#">U.S. EPA (2011a)</a>
DWSHA	NV	NA	<a href="#">U.S. EPA (2012a)</a>
NTP	NV	NA	<a href="#">NTP (2014)</a>
IARC	NV	NA	<a href="#">IARC (2015)</a>
Cal/EPA	NV	NA	<a href="#">Cal/EPA (2011)</a> ; <a href="#">Cal/EPA (2017a)</a> ; <a href="#">Cal/EPA (2017b)</a>
ACGIH	NV	NA	<a href="#">ACGIH (2016)</a>

<sup>a</sup>Sources: ACGIH = American Conference of Governmental Industrial Hygienists; ATSDR = Agency for Toxic Substances and Disease Registry; Cal/EPA = California Environmental Protection Agency; DOE = Department of Energy; DWSHA = Drinking Water Standards and Health Advisories; HEAST = Health Effects Assessment Summary Tables; IARC = International Agency for Research on Cancer; IPCS = International Programme on Chemical Safety; IRIS = Integrated Risk Information System; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; USAPHC = U.S. Army Public Health Command.

<sup>b</sup>Parameters: MEG = military exposure guideline; PAC = protective action criteria; TEEL = temporary emergency exposure limit.

NA = not applicable; NV = not available.



Non-date-limited literature searches were conducted in June 2015 and updated in April 2017 for studies relevant to the derivation of provisional toxicity values for lactonitrile. Searches were conducted using the U.S. EPA's Health and Environmental Research Online (HERO) database of scientific literature. HERO searches the following databases: PubMed, ToxLine (including TSCATS1), and Web of Science. The following databases were searched outside of HERO for health-related data: American Conference of Governmental Industrial Hygienists (ACGIH), Agency for Toxic Substances and Disease Registry (ATSDR), California Environmental Protection Agency (Cal/EPA), U.S. EPA Integrated Risk Information System (IRIS), U.S. EPA Health Effects Assessment Summary Tables (HEAST), U.S. EPA Office of Water (OW), U.S. EPA TSCATS2/TSCATS8e, U.S. HPV, European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Japan Existing Chemical Data Base (JECDB), European Chemicals Agency (ECHA), OECD SIDS, OECD International Uniform Chemical Information Database (IUCLID), OECD HPV, National Institute for Occupational Safety and Health (NIOSH), National Toxicology Program (NTP), Occupational Safety and Health Administration (OSHA), and Defense Technical Information Center (DTIC).

### **REVIEW OF POTENTIALLY RELEVANT DATA (NONCANCER AND CANCER)**

Tables 3A and 3B provide overviews of the relevant noncancer and cancer databases, respectively, for lactonitrile and include all potentially relevant repeated-dose short-term-, subchronic-, and chronic-duration studies as well as reproductive and developmental toxicity studies. Principal studies are identified in bold. The phrase "statistical significance" and the term "significant(ly)," used throughout the document, indicate a *p*-value of < 0.05 unless otherwise specified.

Table 3A. Summary of Potentially Relevant Noncancer Data for Lactonitrile (CASRN 78-97-7)							
Category <sup>a</sup>	Number of Male/Female, Strain, Species, Study Type, Reported Doses, Study Duration	Dosimetry <sup>b</sup>	Critical Effects	NOAEL <sup>b</sup>	LOAEL <sup>b</sup>	Reference (comments)	Notes <sup>c</sup>
<b>Human</b>							
1. Oral (mg/kg-d)							
ND							
2. Inhalation (mg/m <sup>3</sup> )							
ND							
<b>Animal</b>							
1. Oral (mg/kg-d)							
Combined subchronic toxicity and R/D screening study	10 M/10 F, Crj:CD(SD) rat; gavage (vehicle not specified); 7 d/wk, 6 wk (2 wk prematuring through 2 wk postmating [M] or PND 3 [F])	ADD: 0, 1.2, 6, 30	Systemic: Increased absolute and relative liver weights, and centrilobular hypertrophy in males; increased absolute liver weight in females; transient clinical signs of toxicity in both sexes (hypolocomotion, hypopnea, salivation)  R/D: No observed effects	Systemic: 6  R/D: 30	Systemic: 30  R/D: NDr	<a href="#">UNEP (2003); Mitsubishi Chemical Safety Institute Ltd. (1992b)</a>	NPR, PS Based on UNEP summary of Japanese language publication with data tables in English
2. Inhalation (mg/m <sup>3</sup> )							
ND							

<sup>a</sup>Duration categories are defined as follows: Acute = exposure for ≤24 hours; short term = repeated exposure for 24 hours to ≤30 days; long term (subchronic) = repeated exposure for >30 days ≤10% lifespan for humans (>30 days up to ~90 days in typically used laboratory animal species); and chronic = repeated exposure for >10% lifespan for humans (more than ~90 days to 2 years in typically used laboratory animal species) ([U.S. EPA, 2002](#)).

<sup>b</sup>Dosimetry: Values are presented as ADDs (mg/kg-day) for oral noncancer effects. In contrast to other repeated exposure studies, values from animal gestational exposure studies are not adjusted for exposure duration in calculation of the ADD.

<sup>c</sup>Notes: NPR = not peer reviewed; PS = principal study.

ADD = adjusted daily dose; F = female(s); LOAEL = lowest-observed-adverse-effect level; M = male(s); ND = no data; NDr = not determined; NOAEL = no-observed-adverse-effect level; PND = postnatal day; R/D = reproductive/developmental; UNEP = United Nations Environment Programme.

Table 3B. Summary of Potentially Relevant Cancer Data for Lactonitrile (CASRN 78-97-7)							
Category	Number of Male/Female, Strain, Species, Study Type, Reported Doses, Study Duration	Dosimetry	Critical Effects	NOAEL	LOAEL	Reference (comments)	Notes
<b>Human</b>							
1. Oral (mg/kg-d)							
ND							
2. Inhalation (mg/m <sup>3</sup> )							
ND							
<b>Animal</b>							
1. Oral (mg/kg-d)							
ND							
2. Inhalation (mg/m <sup>3</sup> )							
ND							

LOAEL = lowest-observed-adverse-effect level; ND = no data; NOAEL = no-observed-adverse-effect level.

## HUMAN STUDIES

Human data are limited to a single case report. A fatal case of poisoning, attributed to lactonitrile, was reported in a worker exposed to lactonitrile while cleaning discharge pipes in a factory where acrylonitrile was produced ([Nagata et al., 1968](#)). The man experienced severe headache, nausea, palpitation, and abdominal pain while working. He was found unconscious after leaving work and admitted to a hospital under a preliminary diagnosis of cyanide poisoning. Despite medical intervention, the patient died. Autopsy observations included intense posterior lividity, petechial hemorrhages in conjunctiva and in mucosa of the renal pelvis, blood and fluid in pericardium, and marked congestion of all viscera. Gas chromatography was used to verify the presence of acrylonitrile, but showed that lactonitrile was present in much higher quantities in the waste products collected from the factory discharge pipes, the deceased patient's clothing (some items of which, most notably the undershirt and mask, had no acrylonitrile at all), and blood and urine collected postmortem. The authors hypothesized that in the heavy rain that was falling, lactonitrile has dissolved in water and saturated in the thick, tight clothing, from which it was absorbed into the body.

## ANIMAL STUDIES

### Oral Exposures

Repeated-dose oral toxicity data are limited to an unpublished OECD Test Guideline 422 combined repeated-dose and reproductive/developmental (R/D) screening toxicity study conducted by the [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) and written in Japanese. Data tables are presented in English, and an English summary is available in the OECD SIDS dossier ([UNEP, 2003](#)).

[UNEP \(2003\); Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#)

Groups of male and female Crj:CD(SD) rats (10/sex/group) were exposed to lactonitrile (purity 92.3%) at doses of 0, 1.2, 6, or 30 mg/kg-day via gavage, 7 days/week for 14 days before mating, and during a mating period of up to 2 weeks. Daily dosing of females continued through gestation until Postnatal Day (PND) 3; males continued to receive daily gavage doses for 2 weeks postmating (~6 weeks total exposure). It is unclear from the English summary what vehicle was used; however, the summary indicates that concurrent vehicle controls were used. Rats were evaluated daily for mortality and clinical signs of toxicity. Body weight and food consumption were measured weekly. Reproductive endpoints that were evaluated included the length of time between initial pairing and detection of coitus (precoital interval); mating, fertility, implantation, delivery, gestational and viability indices; numbers of corpora lutea, implantation sites, and live and dead offspring; gestation length; and F1 birth weight. On PND 4, all F0 and F1 animals were weighed and sacrificed. At terminal sacrifice, blood was collected from F0 males for clinical chemistry (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP],  $\gamma$ -glutamyl transferase [GGT], total bilirubin, blood urea nitrogen [BUN], creatinine, glucose, total cholesterol, triglyceride, total protein, albumin, calcium, inorganic phosphate, sodium, potassium, chloride) and hematology (red blood cell [RBC] count, white blood cell [WBC] count, and differential, reticulocyte count, platelet count, hematocrit [Hct], hemoglobin [Hb] concentration, mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], mean corpuscular hemoglobin concentration [MCHC]). Based on data presentation, it is unclear whether clinical chemistry or hematological evaluations were conducted in F0 females. The thymus, liver, kidneys, testes, and epididymides from F0 animals were removed and weighed. All F0 and F1 animals were examined grossly, and the liver, heart, spleen, kidneys, adrenals, testes, and epididymides were fixed for histopathological evaluation in

control and high-dose F0 animals. The livers were also examined microscopically in low- and mid-dose F0 males.

One control male died on Day 23 of the experiment due to “manipulation error” (not further defined) and one high-dose female died on Day 41 of the experiment (2 days postpartum) due to disseminated intravascular coagulation which could be treatment-related, but hematology was not evaluated in female rats. No other mortalities occurred. Transient clinical signs of toxicity (decreased locomotion, hypopnea, salivation) were observed in the majority of high-dose males and females; clinical signs of toxicity were not observed in low- or mid-dose rats. No exposure-related changes were observed in body weight or food consumption. All reproductive endpoints were comparable between the exposure and control groups. Slight, but statistically significant increases were observed in several clinical chemistry values in high-dose males, including increased total protein (8%), albumin (9%), and calcium (4%), but the clinical relevance of these small changes is unclear (see Table B-1). Similarly, the relevance of a statistically significant 17% decrease in serum AST is unknown while serum ALT levels did not differ from control (see Table B-1). There is an upward trend in serum bilirubin (75, 200, and 150%, at the low, middle, and high dose, respectively) in F0 males compared with control animals. Elevated bilirubin reached statistical significance at the mid-dose (200%) but not at the high and low dose (see Table B-1).

No significant hematological differences were observed between exposed and control F0 males. Absolute and relative liver weights were statistically and biologically significantly elevated by 23 and 21%, respectively, in F0 males exposed to 30 mg/kg-day lactonitrile, but not in the lower dose F0 male groups; absolute liver weights were biologically (>10%) but not statistically elevated at 30 mg/kg-day in exposed F0 females compared with control animals (see Table B-2). No exposure-related changes were observed in thymus, kidney, testes, or epididymides weights in F0 rats (see Table B-2). Elevated liver weights in high-dose males were accompanied by a statistically significantly increased incidence of grossly observed liver enlargement, and microscopically observed centrilobular hypertrophy; these findings were not observed in any other dose group (see Table B-3). A centrilobular fatty change was observed in a single male rat (1/10 animals) in the high-dose group, but this increase was not statistically significant. No other exposure-related lesions were observed in F0 animals. No abnormal gross findings were reported in exposed F1 pups.

A systemic no-observed-adverse-effect level (NOAEL) of 6 mg/kg-day and a lowest-observed-adverse-effect level (LOAEL) of 30 mg/kg-day are identified based on a >10% increase in absolute and relative liver weights and centrilobular hypertrophy in males, a >10% increase in absolute liver weight in females, and transient clinical signs of toxicity in both sexes (hypolocomotion, hypopnea, salivation).

### **Inhalation Exposures**

No data regarding the chronic- or subchronic-duration toxicity of lactonitrile to animals following repeated-dose inhalation exposure have been identified.

## OTHER DATA (SHORT-TERM TESTS, OTHER EXAMINATIONS)

### Acute Toxicity

Oral median lethal dose (LD<sub>50</sub>) values of 21–87 mg/kg have been reported in rats, with deaths occurring as low as 10 mg/kg ([UNEP, 2003](#); [Hartung, 1993](#); [Mitsubishi Chemical Safety Institute Ltd., 1992a](#); [Smyth et al., 1969](#)). Clinical signs observed in male and female rats (SD/Crj:CD) at acute exposures ( $\geq 21$  mg/kg) included hypopnea, decreased activity, ataxia, pronation, and convulsions; focal hemorrhaging in the lung, and dilation of the atrium were observed in animals that died ([Mitsubishi Chemical Safety Institute Ltd., 1992a](#)). An inhalation study reported no deaths among six rats (sex and strain not reported) exposed to 62.5 ppm of lactonitrile for 4 hours and 6/6 deaths after exposure to 125 ppm for 4 hours ([Smyth et al., 1969](#)). A single application of lactonitrile to the skin of rabbits (sex and strain not reported) resulted in an LD<sub>50</sub> value of 20 mg/kg ([UNEP, 2003](#); [Smyth et al., 1969](#)). For intraperitoneal (i.p.) administration, an LD<sub>50</sub> value of 15 mg/kg was reported in male CD-1 mice ([Kaplita and Smith, 1986](#)). Clinical signs of toxicity exhibited were dyspnea, ataxia, hypothermia, and convulsions. No other details regarding toxic effects were provided. Furthermore, the acute-duration data came from either secondary sources, are published in a foreign language or lack details on experimental methods, thus making interpretation questionable.

### Genotoxicity

A limited number of genotoxicity studies indicate that lactonitrile is not mutagenic to bacteria but has the potential to cause clastogenic effects in yeast and mammalian cells (see Table 4 and below for details).

Lactonitrile was not mutagenic to *Salmonella typhimurium* or *Escherichia coli*, with or without metabolic activation ([FDSC HRI, 2016a](#); [UNEP, 2003](#); [Zeiger et al., 1992](#)). Chromosomal aberrations (CAs) were induced in Chinese hamster lung (CHL) cells, with and without metabolic activation ([FDSC HRI, 2016b](#); [UNEP, 2003](#)). Additionally, lactonitrile induced chromosomal malsegregation and respiratory deficiency in *Saccharomyces cerevisiae* strain D61.M ([Zimmermann and Mohr, 1992](#)).

**Table 4. Summary of Lactonitrile (CASRN 78-97-7) Genotoxicity**

Endpoint	Test System	Doses/Concentrations Tested	Results without Activation <sup>a</sup>	Results with Activation <sup>a</sup>	Comments	Reference(s)
<b>Genotoxicity studies in prokaryotic organisms</b>						
Mutation	<i>Salmonella typhimurium</i> TA97, TA98, TA100, TA1535, and TA1537	0, 0.1, 0.3, 1.0, 3.0, 10, 33, 100, 333, 500 µg/plate	–	–	Cytotoxicity was observed >100 µg/plate.	<a href="#">Zeiger et al. (1992)</a>
Mutation	<i>S. typhimurium</i> TA100, TA1535, TA98, and TA1537	0, 4.69, 9.38, 18.75, 37.5, 75, 150 µg/plate	–	–	Cytotoxicity was observed at 150 µg/plate.	<a href="#">FDSC HRI (2016a)</a> ; <a href="#">UNEP (2003)</a>
Mutation	<i>Escherichia coli</i> WP2 uvrA	0, 75, 150, 300, 600, 1,200, 2,400 µg/plate	–	–	Cytotoxicity was observed at 2,400 µg/plate.	<a href="#">FDSC HRI (2016a)</a> ; <a href="#">UNEP (2003)</a>
<b>Genotoxicity studies in nonmammalian eukaryotic organisms</b>						
Mitotic malsegregation	<i>Saccharomyces cerevisiae</i> strain D61.M; continuous assay (28°C for 16 hr) and cold-shock assay (4 hr at 28°C, 16-hr ice bath, 4 hr at 28°C)	0, 1.96, 2.45, 2.94, 3.43, 4.41, 5.86 mg/mL (continuous assay) 0, 2.45, 2.94, 4.41, 5.87, 7.81, 9.47 mg/mL (cold-shock assay)	+	ND	Increased incidence of malsegregation was observed at ≥2.94 mg/mL in continuous incubation and ≥4.41 mg/mL in cold-shock assay.  An increased incidence of respiratory-deficient cells was noted at ≥4.41 mg/mL in continuous incubation and ≥5.87 mg/mL in cold-shock assay.	<a href="#">Zimmermann and Mohr (1992)</a>
<b>Genotoxicity studies in mammalian cells in vitro</b>						
CAs	CHL cells	0, 0.10, 0.19, 0.38 mg/mL (–S9; 24- or 48-hr incubation) 0, 0.18, 0.36, 0.71 mg/mL (±S9; 6-hr incubation)	+	+	CAs were induced at ≥0.38 mg/mL after 24–48 hr without metabolic activation and at 0.71 mg/mL after 6 hr with or without metabolic activation.  In a separate assay, cytotoxicity was observed at 1.00 mg/mL without metabolic activation and ≥0.38 mg/mL with metabolic activation.	<a href="#">UNEP (2003)</a> ; <a href="#">FDSC HRI (2016b)</a>

<sup>a</sup>+ = positive; – = negative

CA = chromosomal aberration; CHL = Chinese hamster lung; ND = no data.

## DERIVATION OF PROVISIONAL VALUES

Tables 5 and 6 present summaries of noncancer and cancer reference values, respectively.

<b>Table 5. Summary of Noncancer Reference Values for Lactonitrile (CASRN 78-97-7)</b>							
<b>Toxicity Type (units)</b>	<b>Species/Sex</b>	<b>Critical Effect</b>	<b>p-Reference Value</b>	<b>POD Method</b>	<b>POD (HED)</b>	<b>UF<sub>C</sub></b>	<b>Principal Study</b>
Screening Subchronic p-RfD (mg/kg-d)	Rat/F	Elevated absolute liver weight	$2 \times 10^{-3}$	BMDL <sub>10</sub>	0.5	300	<a href="#">Mitsubishi Chemical Safety Institute Ltd. (1992b)</a>
Screening Chronic p-RfD (mg/kg-d)	Rat/F	Elevated absolute liver weight	$2 \times 10^{-4}$	BMDL <sub>10</sub>	0.5	3,000	<a href="#">Mitsubishi Chemical Safety Institute Ltd. (1992b)</a>
Subchronic p-RfC (mg/m <sup>3</sup> )	NDr						
Chronic p-RfC (mg/m <sup>3</sup> )	NDr						

BMDL<sub>10</sub> = 10% benchmark dose lower confidence limit; F = female(s); HED = human equivalent dose; NDr = not determined; POD = point of departure; p-RfC = provisional reference concentration; p-RfD = provisional reference dose; UF<sub>C</sub> = composite uncertainty factor.

<b>Table 6. Summary of Cancer Reference Values for Lactonitrile (CASRN 78-97-7)</b>				
<b>Toxicity Type (units)</b>	<b>Species/Sex</b>	<b>Tumor Type</b>	<b>Cancer Value</b>	<b>Principal Study</b>
p-OSF (mg/kg-d) <sup>-1</sup>	NDr			
p-IUR (mg/m <sup>3</sup> ) <sup>-1</sup>	NDr			

NDr = not determined; p-IUR = provisional inhalation unit risk; p-OSF = provisional oral slope factor.

## DERIVATION OF ORAL REFERENCE DOSES

The available human and animal data are not considered sufficiently reliable to use in deriving subchronic or chronic provisional reference doses (p-RfDs) for lactonitrile. Repeated-dose oral toxicity data for lactonitrile are limited to an unpublished OECD combined repeated-dose and R/D screening toxicity test conducted by the [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) and written in Japanese. Because the study is not available in English, it cannot be independently reviewed; therefore, it is not appropriate to use as the basis of a provisional toxicity value. However, study data tables are provided in English, and there is an English language summary of the study in the OECD SIDS dossier ([UNEP, 2003](#)); therefore, this study is suitable for the derivation of “screening-level” values for subchronic and chronic oral exposure to lactonitrile (see Appendix A). Further, the NOAEL for systemic toxicity (6 mg/kg-day), identified in the [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) summary is close to LD<sub>50</sub> values (21–87 mg/kg-day) derived from several acute toxicity studies ([UNEP, 2003](#); [Hartung, 1993](#); [Mitsubishi Chemical Safety Institute Ltd., 1992a](#); [Smyth et al., 1969](#)). The



close proximity of LD<sub>50</sub> values to NOAELs found in the principal study supports the derivation of screening values rather than provisional values.

#### DERIVATION OF INHALATION REFERENCE CONCENTRATIONS

No subchronic- or chronic-duration, repeated-exposure studies were located regarding toxicity of lactonitrile to humans or animals by inhalation; therefore, neither subchronic nor chronic provisional reference concentrations (p-RfCs) are derived.

#### CANCER WEIGHT-OF-EVIDENCE DESCRIPTOR

No relevant cancer data are available. Under the 2005 *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005](#)), there is “*Inadequate Information to Assess Carcinogenic Potential*” for lactonitrile by either oral or inhalation exposure (see Table 7).

Table 7. Cancer Weight-of-Evidence Descriptor for Lactonitrile (CASRN 78-97-7)			
Possible WOE Descriptor	Designation	Route of Entry (oral, inhalation, or both)	Comments
“ <i>Carcinogenic to Humans</i> ”	NS	NA	There are no human data to support this.
“ <i>Likely to Be Carcinogenic to Humans</i> ”	NS	NA	There are no suitable human or animal studies to support this.
“ <i>Suggestive Evidence of Carcinogenic Potential</i> ”	NS	NA	There are no suitable human or animal studies to support this.
“ <i>Inadequate Information to Assess Carcinogenic Potential</i> ”	Selected	Both	Available studies are insufficient to assess carcinogenic potential.
“ <i>Not Likely to Be Carcinogenic to Humans</i> ”	NS	NA	There are no suitable human or animal studies to support this.

NA = not applicable; NS = not selected; WOE = weight of evidence.

#### DERIVATION OF PROVISIONAL CANCER POTENCY VALUES

The absence of suitable data precludes development of cancer potency values for lactonitrile.

## APPENDIX A. SCREENING PROVISIONAL VALUES

For reasons noted in the main Provisional Peer-Reviewed Toxicity Value (PPRTV) document, it is inappropriate to derive provisional toxicity values for lactonitrile. However, information is available for this chemical, which although insufficient to support derivation of a provisional toxicity value under current guidelines, may be of limited use to risk assessors. In such cases, the Superfund Health Risk Technical Support Center summarizes available information in an appendix and develops a “screening value.” Appendices receive the same level of internal and external scientific peer review as the main documents to ensure their appropriateness within the limitations detailed in the document. Users of screening toxicity values in an appendix to a PPRTV assessment should understand that there is considerably more uncertainty associated with the derivation of an appendix screening toxicity value than for a value presented in the body of the assessment. Questions or concerns about the appropriate use of screening values should be directed to the Superfund Health Risk Technical Support Center.

### Derivation of a Screening Subchronic Provisional Reference Dose

The unpublished Japanese-language Organisation for Economic Co-operation and Development (OECD) combined repeated-dose and reproductive/developmental (R/D) screening toxicity test conducted by the [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) and summarized in [UNEP \(2003\)](#). The [UNEP \(2003\)](#) described the report as “well controlled” and performed according to Good Laboratory Practices (GLP), and is considered the principal study for use in deriving the screening provisional reference doses (p-RfDs). The critical effect was increased absolute liver weight in female rats observed at 30 mg/kg-day.

The subchronic-duration study by [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) conducted daily administration of lactonitrile by gavage to Crj:CD(SD) rats (10/sex/group) for 6 weeks, including prior to mating and during a mating period. The report included a comprehensive assessment of body weight, hematology (males only), serum chemistry (males only), organ weights, and gross pathology of various organs. The authors also performed a microbiological exam of several organs at the control (0 mg/kg-day) and high dose (30 mg/kg-day), and male livers at all doses.

The study, however, is available as a secondary summary source and foreign language publication. A lowest-observed-adverse-effect level (LOAEL) of 30 mg/kg-day with a corresponding no-observed-adverse-effect level (NOAEL) of 6 mg/kg-day is identified based on >10% increase in absolute and relative liver weights in male F0 rats, >10% increase in absolute liver weight in female rats, and clinical signs of toxicity in male and female rats.

Potential points of departure (PODs) (see Table A-1) were modeled using the EPA’s Benchmark Dose Software (BMDS, Version 2.6). The incidence data for centrilobular hypertrophy and clinical signs of toxicity were not suitable for benchmark dose (BMD) modeling because effects were only observed in high-dose animals (zero incidence in control and lower-dose animals). Details of the BMD modeling can be found in Appendix C. PODs considered for derivation of the screening subchronic p-RfD are presented in Table A-1. Bilirubin was elevated (75, 200, and 150% respectively) at 1.2, 6, and 30 mg lactonitrile/kg-day in male rats, and the effect is consistent with liver toxicity. But the effect was not considered as a POD because only the mid-dose (6 mg/kg-day) was statistically significant. Further, because

the reference range of total bilirubin varies by up to 1,200% in humans ([Chernecky and Berger, 2013](#)) and a comparable amount in CD rats ([Giknis and Clifford, 2006](#)), the toxicological significance of a 200% elevation in bilirubin is uncertain.

<b>Table A-1. PODs Considered for Derivation of the Screening Subchronic p-RfD from the 6-Week Gavage Study in Crj:CD(SD) F0 Rats (2 Weeks Premating through 2 Weeks Postmating [Males] or PND 3 [Females])<sup>a</sup></b>					
Species/Sex	Critical Effect	NOAEL (mg/kg-d)	LOAEL (mg/kg-d)	POD Method	POD (mg/kg-d)
Rat/M	Increased absolute liver weight	6	30	BMDL <sub>10</sub>	10
Rat/M	Increased relative liver weight	6	30	BMDL <sub>10</sub>	10
Rat/F	Increased absolute liver weight	6	30	BMDL <sub>10</sub>	2
Rat/M	Centrilobular hypertrophy	6	30	NOAEL	6
Rat/M & F	Clinical signs of toxicity	6	30	NOAEL	6

<sup>a</sup>[Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#).

BMDL<sub>10</sub> = 10% benchmark dose lower confidence limit; F = female(s); LOAEL = lowest-observed-adverse-effect level; M = male(s); NOAEL = no-observed-adverse-effect level; PND = postnatal day; POD = point of departure; p-RfD = provisional reference dose.

The lowest available POD is a 10% benchmark dose lower confidence limit (BMDL<sub>10</sub>) of 2 mg/kg-day for female rats with elevated absolute liver weight that is biologically significant (>10% change). This POD is protective of other effects observed following lactonitrile exposure, including liver-weight changes in male and female rats. These liver-weight increases are consistent with the centrilobular hypertrophy, gross liver enlargement, and centrilobular fatty changes reported in male rats. Based on the consistency in these effects within the study, **the BMDL<sub>10</sub> for elevated absolute liver weight in female rats (2 mg/kg-day) is selected as the POD for derivation of the screening subchronic p-RfD.**

The BMDL<sub>10</sub> of 2 mg/kg-day was converted to a human equivalent dose (HED) according to current [U.S. EPA \(2011b\)](#) guidance. In *Recommended Use of Body Weight<sup>3/4</sup> as the Default Method in Derivation of the Oral Reference Dose* ([U.S. EPA, 2011b](#)), the EPA endorses body-weight scaling to the 3/4 power (i.e., BW<sup>3/4</sup>) as a default to extrapolate toxicologically equivalent doses of orally administered agents from all laboratory animals to humans for the purpose of deriving a p-RfD from effects that are not portal-of-entry effects.

Following [U.S. EPA \(2011b\)](#) guidance, the POD for systemic toxicity is converted to an HED through the application of a dosimetric adjustment factor (DAF)<sup>2</sup> derived as follows:

$$\text{DAF} = (\text{BW}_a^{1/4} \div \text{BW}_h^{1/4})$$

where

DAF = dosimetric adjustment factor  
 BW<sub>a</sub> = animal body weight  
 BW<sub>h</sub> = human body weight

Using a reference BW<sub>a</sub> of 0.25 kg for rats and a reference BW<sub>h</sub> of 70 kg for humans, the resulting DAF is 0.24 ([U.S. EPA, 2011b](#)). Applying this DAF to the BMDL<sub>10</sub> of 2 mg/kg-day yields a POD (HED) as follows:

$$\begin{aligned} \text{POD (HED)} &= \text{BMDL}_{10} \text{ (mg/kg-day)} \times \text{DAF} \\ &= 2 \text{ mg/kg-day} \times 0.24 \\ &= 0.5 \text{ mg/kg-day} \end{aligned}$$

The screening subchronic p-RfD for lactonitrile was derived using the POD (HED) and a composite uncertainty factor (UF<sub>C</sub>) of 300 (reflecting an interspecies uncertainty factor [UF<sub>A</sub>] of 3, an intraspecies uncertainty factor [UF<sub>H</sub>] of 10, and a database uncertainty factor [UF<sub>D</sub>] of 10):

$$\begin{aligned} \text{Screening Subchronic p-RfD} &= \text{POD (HED)} \div \text{UF}_C \\ &= 0.5 \text{ mg/kg-day} \div 300 \\ &= 2 \times 10^{-3} \text{ mg/kg-day} \end{aligned}$$

Table A-2 summarizes the uncertainty factors for the screening subchronic p-RfD for lactonitrile.

---

<sup>2</sup>As described in detail in *Recommended Use of Body Weight<sup>3/4</sup> as the Default Method in Derivation of the Oral Reference Dose* ([U.S. EPA, 2011b](#)), rate-related processes scale across species in a manner related to both the direct (BW<sup>1/1</sup>) and allometric scaling (BW<sup>3/4</sup>) aspects such that BW<sup>3/4</sup> ÷ BW<sup>1/1</sup> = BW<sup>-1/4</sup>, converted to a DAF = BW<sub>a</sub><sup>1/4</sup> ÷ BW<sub>h</sub><sup>1/4</sup>.

Table A-2. Uncertainty Factors for the Screening Subchronic p-RfD for Lactonitrile (CASRN 78-97-7)		
UF	Value	Justification
UF <sub>A</sub>	3	A UF <sub>A</sub> of 3 (10 <sup>0.5</sup> ) is applied to account for uncertainty in characterizing the toxicokinetic or toxicodynamic differences between rats and humans following oral lactonitrile treatment. The toxicokinetic uncertainty has been accounted for by calculating an HED through application of a DAF as outlined in the EPA's <i>Recommended Use of Body Weight</i> <sup>3/4</sup> as the Default Method in Derivation of the Oral Reference Dose (U.S. EPA, 2011b).
UF <sub>D</sub>	10	A UF <sub>D</sub> of 10 is applied to account for the limited toxicity database for lactonitrile, specifically the lack of a repeated-dose systemic toxicity study longer than 6 wk; lack of a repeated-dose toxicity study in a second species; lack of a comprehensive evaluation in females; reproductive and developmental toxicity in a second species; and the lack of evaluation of CNS toxicity based on behavioral and clinical signs of toxicity.
UF <sub>H</sub>	10	A UF <sub>H</sub> of 10 is applied for intraspecies variability to account for human-to-human variability in susceptibility in the absence of quantitative information to assess the toxicokinetics and toxicodynamics of lactonitrile in humans.
UF <sub>L</sub>	1	A UF <sub>L</sub> of 1 is applied because the POD is a BMDL <sub>10</sub> .
UF <sub>S</sub>	1	A UF <sub>S</sub> of 1 is applied because a subchronic-duration study was selected as the principal study.
UF <sub>C</sub>	300	Composite UF = UF <sub>A</sub> × UF <sub>D</sub> × UF <sub>H</sub> × UF <sub>L</sub> × UF <sub>S</sub> .

BMDL<sub>10</sub> = 10% benchmark dose lower confidence limit; CNS = central nervous system; DAF = dosimetric adjustment factor; HED = human equivalent dose; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; POD = point of departure; UF = uncertainty factor; UF<sub>A</sub> = interspecies uncertainty factor; UF<sub>C</sub> = composite uncertainty factor; UF<sub>D</sub> = database uncertainty factor; UF<sub>H</sub> = intraspecies variability uncertainty factor; UF<sub>L</sub> = LOAEL-to-NOAEL uncertainty factor; UF<sub>S</sub> = subchronic-to-chronic uncertainty factor.

### Derivation of a Screening Chronic Provisional Reference Dose

The unpublished Japanese-language OECD combined repeated-dose and R/D screening toxicity test conducted by the [Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#) is considered the principal study for use in deriving the screening chronic p-RfD. No studies evaluating chronic-duration exposure to lactonitrile have been identified. Therefore, the BMDL<sub>10</sub> of 2 mg/kg-day for elevated absolute liver weight in female rats is used as the POD for the screening chronic p-RfD. An additional subchronic-to-chronic uncertainty factor (UF<sub>S</sub>) of 10 is applied to account for extrapolation from a subchronic-duration study.

The screening chronic p-RfD for lactonitrile is derived using the POD (HED) and a UF<sub>C</sub> of 3,000 (reflecting a UF<sub>A</sub> of 3, a UF<sub>H</sub> of 10, a UF<sub>D</sub> of 10, and a UF<sub>S</sub> of 10):

$$\begin{aligned}
 \text{Screening Chronic p-RfD} &= \text{POD (HED)} \div \text{UF}_C \\
 &= 0.5 \text{ mg/kg-day} \div 3,000 \\
 &= 2 \times 10^{-4} \text{ mg/kg-day}
 \end{aligned}$$

Table A-3 summarizes the uncertainty factors for the screening chronic p-RfD for lactonitrile.

**Table A-3. Uncertainty Factors for the Screening Chronic p-RfD for Lactonitrile (CASRN 78-97-7)**

UF	Value	Justification
UF <sub>A</sub>	3	A UF <sub>A</sub> of 3 ( $10^{0.5}$ ) is applied to account for uncertainty in characterizing the toxicokinetic or toxicodynamic differences between rats and humans following oral lactonitrile treatment. The toxicokinetic uncertainty has been accounted for by calculating an HED through application of a DAF as outlined in the EPA's <i>Recommended Use of Body Weight<sup>3/4</sup> as the Default Method in Derivation of the Oral Reference Dose</i> ( <a href="#">U.S. EPA, 2011b</a> ).
UF <sub>D</sub>	10	A UF <sub>D</sub> of 10 is applied to account for the limited toxicity database for lactonitrile, specifically the lack of a repeated-dose systemic toxicity study longer than 6 wk; lack of a repeated-dose toxicity study in a second species; lack of a comprehensive evaluation in females; reproductive and developmental toxicity in a second species; and the lack of evaluation of CNS toxicity based on behavioral and clinical signs of toxicity.
UF <sub>H</sub>	10	A UF <sub>H</sub> of 10 is applied for intraspecies variability to account for human-to-human variability in susceptibility in the absence of quantitative information to assess the toxicokinetics and toxicodynamics of lactonitrile in humans.
UF <sub>L</sub>	1	A UF <sub>L</sub> of 1 is applied because the POD is a BMDL <sub>10</sub> .
UF <sub>S</sub>	10	A UF <sub>S</sub> of 10 is applied because a subchronic-duration study was selected as the principal study.
UF <sub>C</sub>	3,000	Composite UF = UF <sub>A</sub> × UF <sub>D</sub> × UF <sub>H</sub> × UF <sub>L</sub> × UF <sub>S</sub> .

BMDL<sub>10</sub> = 10% benchmark dose lower confidence limit; CNS = central nervous system; DAF = dosimetric adjustment factor; HED = human equivalent dose; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; POD = point of departure; UF = uncertainty factor; UF<sub>A</sub> = interspecies uncertainty factor; UF<sub>C</sub> = composite uncertainty factor; UF<sub>D</sub> = database uncertainty factor; UF<sub>H</sub> = intraspecies variability uncertainty factor; UF<sub>L</sub> = LOAEL-to-NOAEL uncertainty factor; UF<sub>S</sub> = subchronic-to-chronic uncertainty factor.

## APPENDIX B. DATA TABLES

<b>Table B-1. Selected Clinical Chemistry Endpoints in Male Crj:CD(SD) F0 Rats Exposed to Lactonitrile by Gavage up to 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)<sup>a</sup></b>				
Endpoint <sup>b</sup>	Exposure Group, mg/kg-d			
	0	1.2	6	30
GOT (AST) (IU/L)	81 ± 12.6	77 ± 10.8 (−4.9%)	77 ± 10.5 (−4.9%)	67 ± 5.9* (−17.3%)
GPT (ALT) (IU/L)	27 ± 6.4	27 ± 7.3 (0%)	25 ± 4.0 (−7.4%)	24 ± 6.4 (−11.1%)
ALP (IU/L)	251 ± 65.8	236 ± 37.3 (−6%)	219 ± 38.7 (−12.7%)	225 ± 47.7 (−10.4%)
Total bilirubin (mg/dL)	0.04 ± 0.05	0.07 ± 0.05 (+75%)	0.12 ± 0.04* (+200%)	0.10 ± 0.07 (+150%)
Total protein (g/dL)	6.43 ± 0.276	6.42 ± 0.167 (−0.2%)	6.53 ± 0.233 (+1.6%)	6.93 ± 0.276** (+7.8%)
Albumin (g/dL)	3.85 ± 0.122	3.79 ± 0.094 (−1.6%)	3.88 ± 0.134 (+0.8%)	4.2 ± 0.169** (+9.1%)
Calcium (mg/dL)	9.1 ± 0.25	9.1 ± 0.19 (0%)	9.2 ± 0.3 (+1.1%)	9.5 ± 0.2* (+4.4%)

<sup>a</sup>[Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#).

<sup>b</sup>Values are reported as mean ± SD for 9 control rats and 10 rats/exposure group.

\*Statistically significantly different from control value at  $p < 0.05$ , as reported by the study authors.

\*\*Statistically significantly different from control value at  $p < 0.01$ , as reported by the study authors.

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate amino transferase; GOT = glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transaminase; SD = standard deviation.

**Table B-2. Body and Organ Weights for Male and Female Crj:CD(SD) F0 Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating [Males] or PND 3 [Females])<sup>a</sup>**

Endpoint <sup>b</sup>	Exposure Group, mg/kg-d			
	0	1.2	6	30
<b>Male</b>				
<b>Sample size</b>	<b>9</b>	<b>10</b>	<b>10</b>	<b>10</b>
Final body weight (g)	474 ± 31.0	472 ± 33.7 (−0.4%)	479 ± 36.7 (+1.1%)	480 ± 28.7 (+1.3%)
<b>Liver</b>				
Absolute (g)	12.94 ± 1.675	12.92 ± 1.712 (−0.2%)	13.23 ± 1.798 (+2.2%)	15.87 ± 1.661** (+22.6%)
Relative (%)	2.72 ± 0.201	2.73 ± 0.203 (+0.4%)	2.75 ± 0.176 (+1.1%)	3.30 ± 0.261** (+21.3%)
<b>Kidney</b>				
Absolute (g)	3.04 ± 0.271	2.97 ± 0.204 (−2.3%)	3.10 ± 0.278 (+2%)	3.12 ± 0.334 (+2.6%)
Relative (%)	0.64 ± 0.041	0.63 ± 0.016 (−1.6%)	0.65 ± 0.020 (+1.6%)	0.65 ± 0.062 (+1.6%)
<b>Thymus</b>				
Absolute (mg)	340 ± 62.7	382 ± 67.4 (+12.4%)	360 ± 95.2 (+5.9%)	381 ± 87.1 (+12.1%)
Relative (%)	0.072 ± 0.016	0.081 ± 0.016 (+12.5%)	0.075 ± 0.017 (+4.2%)	0.079 ± 0.016 (+9.7%)
<b>Testes</b>				
Absolute (g)	3.17 ± 0.168	3.17 ± 0.272 (0%)	3.33 ± 0.187 (+5%)	3.22 ± 0.389 (+1.6%)
Relative (%)	0.67 ± 0.070	0.67 ± 0.062 (0%)	0.70 ± 0.062 (+4.5%)	0.67 ± 0.086 (0%)
<b>Epididymis</b>				
Absolute (g)	1.26 ± 0.068	1.25 ± 0.089 (−0.8%)	1.27 ± 0.109 (+0.8%)	1.30 ± 0.144 (+3.2%)
Relative (%)	0.27 ± 0.025	0.26 ± 0.027 (−3.7%)	0.27 ± 0.026 (0%)	0.27 ± 0.034 (0%)



**Table B-2. Body and Organ Weights for Male and Female Crj:CD(SD) F0 Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating [Males] or PND 3 [Females])<sup>a</sup>**

Endpoint <sup>b</sup>	Exposure Group, mg/kg-d			
	0	1.2	6	30
<b>Female</b>				
<b>Sample size</b>	<b>9</b>	<b>10</b>	<b>9</b>	<b>9</b>
Final body weight (g)	303 ± 15.6	307 ± 13.4 (+1.3%)	312 ± 20.5 (+3%)	315 ± 16.6 (+4%)
<b>Liver</b>				
Absolute (g)	12.61 ± 0.946	12.59 ± 1.135 (−0.2%)	13.62 ± 0.941 (+8%)	13.9 ± 1.33 (+10.2%)
Relative (%)	4.17 ± 0.347	4.10 ± 0.252 (−1.7%)	4.37 ± 0.206 (+4.8%)	4.41 ± 0.353 (+5.8%)
<b>Kidney</b>				
Absolute (g)	1.96 ± 0.174	1.98 ± 0.188 (+1%)	2.00 ± 0.105 (+2%)	1.98 ± 0.174 (+1%)
Relative (%)	0.65 ± 0.067	0.65 ± 0.056 (0%)	0.64 ± 0.031 (−1.5%)	0.63 ± 0.051 (−3.1%)
<b>Thymus</b>				
Absolute (mg)	239 ± 53.6	253 ± 54.6 (+5.9%)	224 ± 51.7 (−6.3%)	231 ± 73.6 (−3.3%)
Relative (%)	0.079 ± 0.019	0.082 ± 0.015 (+3.8%)	0.071 ± 0.015 (−10.1%)	0.073 ± 0.020 (−7.6%)

<sup>a</sup>Mitsubishi Chemical Safety Institute Ltd. (1992b).

<sup>b</sup>Values are reported as mean ± SD for 9–10 rats/group.

\*Statistically significantly different from control value at  $p < 0.05$ , as reported by the study authors.

\*\*Statistically significantly different from control value at  $p < 0.01$ , as reported by the study authors.

PND = postnatal day; SD = standard deviation.

<b>Table B-3. Gross and Microscopic Liver Findings for Male and Female Crj:CD(SD) F0 Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating Through 2 Weeks Postmating [Males] or PND 3 [Females])<sup>a</sup></b>								
Endpoint	Exposure Group, mg/kg-d							
	Male				Female			
	0	1.2	6	30	0	1.2	6	30
<b>Gross necropsy findings</b>								
Liver enlargement	0/9 <sup>b</sup>	0/10	0/10	9/10*	0/10	0/10	0/10	0/9 <sup>c</sup>
<b>Microscopic findings</b>								
Centrilobular hypertrophy	0/9	0/10	0/10	7/10*	0/10	NDr	NDr	0/9
Centrilobular fatty change	0/9	0/10	0/10	1/10	0/10	NDr	NDr	0/9
Glycogen accumulation in hepatocytes	0/9	0/10	0/10	0/10	1/10	NDr	NDr	1/9
Microgranuloma	4/9	4/10	6/10	2/10	0/10	NDr	NDr	0/9

<sup>a</sup>[Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#).

<sup>b</sup>One male died due to manipulation error on the 23<sup>rd</sup> day.

<sup>c</sup>One female died due to disseminated intravascular coagulation on PND 2.

\*Statistically significantly different from control value at  $p < 0.05$ , Fisher's exact test calculated for this review.

NDr = not determined; PND = postnatal day.

## APPENDIX C. BENCHMARK DOSE MODELING RESULTS

### MODELING PROCEDURE FOR CONTINUOUS DATA

Benchmark dose (BMD) modeling of continuous data is conducted with EPA's Benchmark Dose Software (BMDS, Version 2.6). All continuous models available within the software are fit using a default benchmark response (BMR) of 1 standard deviation (SD) relative risk unless a biologically determined BMR is available (e.g., BMR 10% for body weight based on a biologically significant weight loss of 10%), as outlined in the *Benchmark Dose Technical Guidance* (U.S. EPA, 2012b). An adequate fit is judged based on the  $\chi^2$  goodness-of-fit  $p$ -value ( $p > 0.1$ ), magnitude of the scaled residuals in the vicinity of the BMR, and visual inspection of the model fit. In addition to these three criteria for judging adequacy of model fit, a determination is made as to whether the variance across dose groups is homogeneous. If a homogeneous variance model is deemed appropriate based on the statistical test provided by BMDS (i.e., Test 2), the final BMD results are estimated from a homogeneous variance model. If the test for homogeneity of variance is rejected ( $p < 0.1$ ), the model is run again while modeling the variance as a power function of the mean to account for this nonhomogeneous variance. If this nonhomogeneous variance model does not adequately fit the data (i.e., Test 3;  $p$ -value  $< 0.1$ ), the data set is considered unsuitable for BMD modeling. Among all models providing adequate fit, the lowest benchmark dose lower confidence limit/benchmark concentration lower confidence limit (BMDL/BMCL) is selected if the BMDL/BMCL estimates from different models vary >threefold; otherwise, the BMDL/BMCL from the model with the lowest Akaike's information criterion (AIC) is selected as a potential point of departure (POD) from which to derive the provisional reference dose/provisional reference concentration (p-RfD/p-RfC).

### BMD MODELING TO IDENTIFY POTENTIAL PODs FOR THE DERIVATION OF A SCREENING p-RfD

The following data sets were selected for BMD modeling:

- Absolute liver-weight data from male rats administered lactonitrile for 6 weeks (2 weeks pre mating through 2 weeks post mating) ([Mitsubishi Chemical Safety Institute Ltd., 1992b](#))
- Relative liver-weight data from male rats administered lactonitrile for 6 weeks (2 weeks pre mating through 2 weeks post mating) ([Mitsubishi Chemical Safety Institute Ltd., 1992b](#))
- Absolute liver-weight data from female rats administered lactonitrile for 6 weeks (2 weeks pre mating through gestation and Postnatal Day [PND] 3) ([Mitsubishi Chemical Safety Institute Ltd., 1992b](#)).

#### Absolute Liver Weight Data from Male Rats Administered Lactonitrile for 6 Weeks (2 Weeks Pre mating through 2 Weeks Post mating)

The procedure outlined above was applied to the data for increased absolute liver weight in F0 male Crj:CD(SD) rats administered lactonitrile via gavage 7 days/week for 2 weeks prior to mating through 2 weeks post mating (6 weeks total exposure) (see Table C-1). Table C-2 summarizes the BMD modeling results. A BMR of 10% was selected, as this is generally considered a biologically significant change in liver weight for laboratory rodents. With the constant variance model applied, all models, except for the Exponential model 5 and the

Hill model, provided adequate fit to the data. BMDLs for models providing adequate fit were sufficiently close (differed by <threefold), so the model with the lowest AIC was selected (Exponential model 2). Thus, the 10% benchmark dose lower confidence limit (BMDL<sub>10</sub>) of 10 mg/kg-day from this model is selected for this endpoint (see Figure C-1 and the BMD text output for details).

<b>Table C-1. Absolute Liver Weights in Male and Female Rats Administered Lactonitrile via Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)<sup>a</sup></b>				
	<b>Dose, mg/kg-d</b>			
	<b>0</b>	<b>1.2</b>	<b>6</b>	<b>30</b>
<b>Male</b>				
Sample size	9	10	10	10
Mean (g) (% change)	12.94 (0%)	12.92 (−0.2%)	13.23 (+2.2%)	15.87 (+22.6%)
SD (g)	1.675	1.712	1.798	1.661
<b>Female</b>				
Sample size	9	10	9	9
Mean (g) (% change)	12.61 (0%)	12.59 (−0.2%)	13.62 (+8.0%)	13.90 (+10.2%)
SD (g)	0.946	1.135	0.941	1.330

<sup>a</sup>[Mitsubishi Chemical Safety Institute Ltd. \(1992b\).](#)

SD = standard deviation.

**Table C-2. BMD Modeling Results for Increased Absolute Liver Weight in Male Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)**

Model	Variance <i>p</i> -Value <sup>a</sup>	Means <i>p</i> -Value <sup>a</sup>	Scaled Residual: Dose Nearest BMD <sup>b</sup>	AIC	BMD <sub>10</sub> mg/kg-d	BMDL <sub>10</sub> mg/kg-d
<b>Constant variance</b>						
<b>Exponential model 2<sup>c, d</sup></b>	<b>0.99</b>	<b>0.94</b>	<b>-0.2682</b>	<b>82.91</b>	<b>13.45</b>	<b>10.06</b>
Exponential model 3 <sup>c</sup>	0.99	0.94	0.01288	84.79	16.91	10.13
Exponential model 4 <sup>c</sup>	0.99	0.66	-0.3336	84.97	12.61	4.52
Exponential model 5 <sup>c</sup>	0.99	NA	$1.87 \times 10^{-6}$	86.78	7.39	4.70
Hill <sup>c</sup>	0.99	NA	$3.33 \times 10^{-7}$	86.78	7.65	4.58
Linear <sup>c</sup>	0.99	0.91	-0.334	82.97	12.61	9.06
Polynomial (2-degree) <sup>c</sup>	0.99	0.92	0.0181	84.79	17.37	9.16
Polynomial (3-degree) <sup>c</sup>	0.99	0.92	0.0181	84.79	17.37	9.16
Power <sup>c</sup>	0.99	0.94	0.0113	84.79	16.63	9.16

<sup>a</sup>Values <0.10 fail to meet conventional goodness-of-fit criteria.

<sup>b</sup>Scaled residual at dose nearest to the BMD.


<sup>c</sup>Power restricted to  $\geq 1$ .

<sup>d</sup>Selected model.

<sup>e</sup>Coefficients restricted to be positive.

AIC = Akaike's information criterion; BMD = maximum likelihood estimate of the exposure concentration associated with the selected BMR; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e., <sub>10</sub> = exposure concentration associated with 10% extra risk); BMR = benchmark response; NA = not applicable (computation failed).

Exponential Model 2, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Level for BMD



13:58 03/14 2016

**Figure C-1. Exponential (Model 2) for Increased Absolute Liver Weight in Male Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating) ([Mitsubishi Chemical Safety Institute Ltd., 1992b](#))**

### Text Output for Figure C-1:

```
=====
Exponential Model. (Version: 1.9; Date: 01/29/2013)
Input Data File:
C:/BMDS250_2014/Data/PTV-Lactonitrile/exp_AbsLvrWtmale_Exp-ConstantVariance-BMR10_RelDev-Up.(d)
Gnuplot Plotting File:
Mon Mar 14 14:58:33 2016
=====
BMDS Model Run
~~~~~
The form of the response function by Model:
Model 2: Y[dose] = a * exp{sign * b * dose}
Model 3: Y[dose] = a * exp{sign * (b * dose)^d}
Model 4: Y[dose] = a * [c-(c-1) * exp{-b * dose}]
Model 5: Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]

Note: Y[dose] is the median response for exposure = dose;
      sign = +1 for increasing trend in data;
      sign = -1 for decreasing trend.
```

Model 2 is nested within Models 3 and 4.  
Model 3 is nested within Model 5.  
Model 4 is nested within Model 5.

Dependent variable = Mean  
Independent variable = Dose  
Data are assumed to be distributed: normally  
Variance Model:  $\exp(\ln\alpha + \rho \cdot \ln(Y[\text{dose}]))$   
 $\rho$  is set to 0.  
A constant variance model is fit.

Total number of dose groups = 4  
Total number of records with missing values = 0  
Maximum number of iterations = 500  
Relative Function Convergence has been set to: 1e-008  
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact

#### Initial Parameter Values

Variable	Model 2
-----	-----
lnalpha	0.968728
rho(S)	0
a	12.8153
b	0.00705588
c	0
d	1

(S) = Specified

#### Parameter Estimates

Variable	Model 2
-----	-----
lnalpha	0.972076
rho	0
a	12.8113
b	0.00708778
c	0
d	1

#### Table of Stats From Input Data

Dose	N	Obs Mean	Obs Std Dev
-----	---	-----	-----
0	9	12.94	1.675
1.2	10	12.92	1.712
6	10	13.23	1.798
30	10	15.87	1.661

#### Estimated Values of Interest

Dose	Est Mean	Est Std	Scaled Residual
-----	-----	-----	-----
0	12.81	1.626	0.2375
1.2	12.92	1.626	-0.001442
6	13.37	1.626	-0.2682
30	15.85	1.626	0.04529

Other models for which likelihoods are calculated:

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \exp(\alpha + \log(\mu(i)) * \rho)$

Model R:  $Y_{ij} = \mu + e(i)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

#### Likelihoods of Interest

Model	Log(likelihood)	DF	AIC
-----	-----	-----	-----
A1	-38.39019	5	86.78038
A2	-38.34946	8	92.69892
A3	-38.39019	5	86.78038
R	-47.41099	2	98.82198
2	-38.45548	3	82.91096

Additive constant for all log-likelihoods = -35.84. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A2 vs. A1)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does Model 2 fit the data? (A3 vs. 2)

#### Tests of Interest

Test	-2*log(Likelihood Ratio)	D. F.	p-value
-----	-----	-----	-----
Test 1	18.12	6	0.005932
Test 2	0.08146	3	0.994
Test 3	0.08146	3	0.994
Test 4	0.1306	2	0.9368

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. Model 2 seems to adequately describe the data.

Benchmark Dose Computations:

Specified Effect = 0.100000

Risk Type = Relative deviation

Confidence Level = 0.950000



BMD = 13.4471  
BMDL = 10.0646

**Relative Liver Weight Data from Male Rats Administered Lactonitrile for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)**

The procedure outlined above was applied to the data for increased relative liver weight in F0 male Crj:CD(SD) rats administered lactonitrile via gavage, 7 days/week for 2 weeks prior to mating through 2 weeks postmating (6 weeks total exposure) (see Table C-3). Table C-4 summarizes the BMD modeling results. With the constant variance model applied, all models, except for the Exponential model 5 and the Hill model, provided adequate fit to the data. BMDLs for models providing adequate fit were sufficiently close (differed by <threefold), so the model with the lowest AIC was selected (Exponential model 2). Thus, the BMDL<sub>10</sub> of 10 mg/kg-day from this model is selected for this endpoint (see Figure C-2 and the BMD text output for details).

<b>Table C-3. Relative Liver Weights in Male Rats Administered Lactonitrile via Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)<sup>a</sup></b>				
	<b>Dose, mg/kg-d</b>			
	<b>0</b>	<b>1.2</b>	<b>6</b>	<b>30</b>
Sample size	9	10	10	10
Mean (%)	2.72	2.73	2.75	3.30
SD (%)	0.201	0.203	0.176	0.261

<sup>a</sup>[Mitsubishi Chemical Safety Institute Ltd. \(1992b\)](#).

SD = standard deviation.

**Table C-4. BMD Modeling Results for Increased Relative Liver Weight in Male Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating)**

Model	Variance <i>p</i> -Value <sup>a</sup>	Means <i>p</i> -Value <sup>a</sup>	Scaled Residual: Dose Nearest BMD <sup>b</sup>	AIC	BMD <sub>10</sub> mg/kg-d	BMDL <sub>10</sub> mg/kg-d
<b>Constant variance</b>						
<b>Exponential model 2<sup>c, d</sup></b>	<b>0.63</b>	<b>0.63</b>	<b>-0.7994</b>	<b>-78.97</b>	<b>14.19</b>	<b>11.68</b>
Exponential model 3 <sup>c</sup>	0.63	0.92	0.000139	-77.88	20.63	12.09
Exponential model 4 <sup>c</sup>	0.63	0.28	-0.897	-76.74	13.41	10.77
Exponential model 5 <sup>c</sup>	0.63	NA	0.0001451	-75.88	20.33	6.23
Hill <sup>c</sup>	0.63	NA	0.000147	-75.88	20.28	6.28
Linear <sup>c</sup>	0.63	0.56	-0.897	-78.74	13.41	10.77
Polynomial (2-degree) <sup>c</sup>	0.63	0.93	0.000545	-77.88	20.40	11.33
Polynomial (3-degree) <sup>c</sup>	0.63	0.96	$6.82 \times 10^{-5}$	-77.89	22.10	11.33
Power <sup>c</sup>	0.63	0.92	0.00014	-77.88	20.34	11.32

<sup>a</sup>Values <0.10 fail to meet conventional goodness-of-fit criteria.

<sup>b</sup>Scaled residual at dose nearest to the BMD.


<sup>c</sup>Power restricted to  $\geq 1$ .

<sup>d</sup>Selected model.

<sup>e</sup>Coefficients restricted to be positive.

AIC = Akaike's information criterion; BMD = maximum likelihood estimate of the exposure concentration associated with the selected BMR; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e., <sub>10</sub> = exposure concentration associated with 10% extra risk); BMR = benchmark response; NA = not applicable (computation failed).

Exponential Model 2, with BMR of 0.1 Rel. Dev. for the BMD and 0.95 Lower Confidence Level for BM



15:22 03/14 2016

**Figure C-2. Exponential (Model 2) for Increased Relative Liver Weight in Male Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through 2 Weeks Postmating) ([Mitsubishi Chemical Safety Institute Ltd., 1992b](#))**

### Text Output for Figure C-2:

```
=====
Exponential Model. (Version: 1.9; Date: 01/29/2013)
Input Data File:
C:/BMDS250_2014/Data/PTV-Lactonitrile/exp_RelLvrWtmale_Exp-ConstantVariance-BMR10_RelD
ev-Up.(d)
Gnuplot Plotting File:
Mon Mar 14 16:22:11 2016
=====
BMDS Model Run
~~~~~
The form of the response function by Model:
Model 2: Y[dose] = a * exp{sign * b * dose}
Model 3: Y[dose] = a * exp{sign * (b * dose)^d}
Model 4: Y[dose] = a * [c-(c-1) * exp{-b * dose}]
Model 5: Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]
Note: Y[dose] is the median response for exposure = dose;
      sign = +1 for increasing trend in data;
      sign = -1 for decreasing trend.

Model 2 is nested within Models 3 and 4.
```

Model 3 is nested within Model 5.  
Model 4 is nested within Model 5.

Dependent variable = Mean  
Independent variable = Dose  
Data are assumed to be distributed: normally  
Variance Model:  $\exp(\ln\alpha + \rho \cdot \ln(Y[\text{dose}]))$   
 $\rho$  is set to 0.  
A constant variance model is fit.

Total number of dose groups = 4  
Total number of records with missing values = 0  
Maximum number of iterations = 500  
Relative Function Convergence has been set to: 1e-008  
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact

#### Initial Parameter Values

Variable	Model 2
lnalpha	-3.20237
rho(S)	0
a	2.69213
b	0.00666932
c	0
d	1

(S) = Specified

#### Parameter Estimates

Variable	Model 2
lnalpha	-3.17875
rho	0
a	2.69089
b	0.00671863
c	0
d	1

#### Table of Stats From Input Data

Dose	N	Obs Mean	Obs Std Dev
0	9	2.72	0.201
1.2	10	2.73	0.203
6	10	2.75	0.176
30	10	3.3	0.261

#### Estimated Values of Interest

Dose	Est Mean	Est Std	Scaled Residual
0	2.691	0.2041	0.4279
1.2	2.713	0.2041	0.2685
6	2.802	0.2041	-0.7994
30	3.292	0.2041	0.1272

Other models for which likelihoods are calculated:

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2(i)$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \exp(\alpha + \log(\mu(i))) * \rho$

Model R:  $Y_{ij} = \mu + e(i)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

#### Likelihoods of Interest

Model	Log(likelihood)	DF	AIC
A1	42.94622	5	-75.89245
A2	43.80104	8	-71.60208
A3	42.94622	5	-75.89245
R	25.0323	2	-46.0646
2	42.4856	3	-78.97121

Additive constant for all log-likelihoods = -35.84. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A2 vs. A1)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does Model 2 fit the data? (A3 vs. 2)

#### Tests of Interest

Test	-2*log(Likelihood Ratio)	D. F.	p-value
Test 1	37.54	6	< 0.0001
Test 2	1.71	3	0.6348
Test 3	1.71	3	0.6348
Test 4	0.9212	2	0.6309

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. Model 2 seems to adequately describe the data.

#### Benchmark Dose Computations:

Specified Effect = 0.100000

Risk Type = Relative deviation

Confidence Level = 0.950000

BMD = 14.186  
 BMDL = 11.6832

**Absolute Liver Weight Data from Female Rats Administered Lactonitrile for 6 Weeks  
(2 Weeks Premating through PND 3)**

The procedure outlined above was applied to the data for increased (10.2%) absolute liver weight in F0 female Crj:CD(SD) rats administered lactonitrile via gavage 7 days/week for 2 weeks prior to mating through PND 3 (6 weeks total exposure) (see Table C-1). Table C-5 summarizes the BMD modeling results. With the constant variance model applied, all models, except for the Exponential model 5 and the Hill model, provided adequate fit to the data. The BMDLs for models providing adequate fit differed by >threefold, so the model with the lowest BMDL<sub>10</sub> was selected (Exponential model 4). Thus, the BMDL<sub>10</sub> of 2 mg/kg-day from this model is selected for this endpoint (see Figure C-3 and the BMD text output for details).

**Table C-5. BMD Modeling Results for Increased Absolute Liver Weight in Female Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through PND 3)**

Model	Variance <i>p</i> -Value <sup>a</sup>	Means <i>p</i> -Value <sup>a</sup>	Scaled Residual: Dose Nearest BMD <sup>c</sup>	AIC	BMD <sub>10</sub> mg/kg-d	BMDL <sub>10</sub> mg/kg-d
<b>Constant variance</b>						
Exponential model 2 <sup>c</sup>	0.6741	0.1585	-0.27	49.55785	32.1179	19.991
Exponential model 3 <sup>c</sup>	0.6741	0.1585	0.01	49.55785	32.1179	19.991
<b>Exponential model 4<sup>c, d</sup></b>	<b>0.6741</b>	<b>0.4235</b>	<b>-0.33</b>	<b>48.51447</b>	<b>9.40352</b>	<b>2.17676</b>
Exponential model 5 <sup>c</sup>	0.6741	NA	$1.87 \times 10^{-6}$	49.8756	6.57339	1.25823
Hill <sup>c</sup>	0.6741	NA	$3.33 \times 10^{-7}$	49.8756	7.30683	NA
Linear <sup>c</sup>	0.6741	0.1638	-0.33	49.491986	31.8573	19.3007
Polynomial (2-degree) <sup>c</sup>	0.6741	0.1638	0.02	49.491986	31.8573	19.3007
Polynomial (3-degree) <sup>c</sup>	0.6741	0.1638	0.02	49.491986	31.8573	19.3007
Power <sup>c</sup>	0.6741	0.1638	0.01	49.491986	31.8573	19.3007

<sup>a</sup>Values <0.10 fail to meet conventional goodness-of-fit criteria.

<sup>b</sup>Scaled residual at dose nearest to the BMD.


<sup>c</sup>Power restricted to  $\geq 1$ .

<sup>d</sup>Selected model.

<sup>e</sup>Coefficients restricted to be positive.

AIC = Akaike's information criterion; BMD = maximum likelihood estimate of the exposure concentration associated with the selected BMR; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e., <sub>10</sub> = exposure concentration associated with 10% extra risk); BMR = benchmark response; NA = not applicable (computation failed); PND = postnatal day.





**Figure C-3. Exponential (Model 4) for Increased Absolute Liver Weight in Female Rats Exposed to Lactonitrile by Gavage for 6 Weeks (2 Weeks Premating through PND 3)**  
([Mitsubishi Chemical Safety Institute Ltd., 1992b](#))

### Text Output for Figure C-3:

```
=====
Exponential Model. (Version: 1.10; Date: 01/12/2015)
Input Data File: C:/Users/CCUBBIS/Desktop/LAC Female
Rat/exp_LACFemaleABSLiver_Exp-ConstantVariance-BMR10-Up.(d)
Gnuplot Plotting File:
Wed Nov 23 10:44:58 2016
=====
```

BMDS Model Run

~~~~~

The form of the response function by Model:

```
Model 2: Y[dose] = a * exp{sign * b * dose}
Model 3: Y[dose] = a * exp{sign * (b * dose)^d}
Model 4: Y[dose] = a * [c-(c-1) * exp{-b * dose}]
Model 5: Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]
```

Note: Y[dose] is the median response for exposure = dose;  
sign = +1 for increasing trend in data;  
sign = -1 for decreasing trend.

Model 2 is nested within Models 3 and 4.  
Model 3 is nested within Model 5.  
Model 4 is nested within Model 5.

Dependent variable = Mean  
Independent variable = Dose  
Data are assumed to be distributed: normally  
Variance Model:  $\exp(\ln\alpha + \rho \cdot \ln(Y[\text{dose}]))$   
 $\rho$  is set to 0.  
A constant variance model is fit.

Total number of dose groups = 4  
Total number of records with missing values = 0  
Maximum number of iterations = 500  
Relative Function Convergence has been set to: 1e-008  
Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact

#### Initial Parameter Values

| Variable | Model 4     |
|----------|-------------|
| -----    | -----       |
| lnalpha  | 0.0776715   |
| rho      | 0 Specified |
| a        | 11.9605     |
| b        | 0.0493555   |
| c        | 1.22027     |
| d        | 1 Specified |

#### Parameter Estimates

| Variable | Model 4   | Std. Err. |
|----------|-----------|-----------|
| -----    | -----     | -----     |
| lnalpha  | 0.0949857 | 0.255662  |
| a        | 12.4722   | 0.296315  |
| b        | 0.20211   | 0.144696  |
| c        | 1.11758   | 0.0376269 |

#### Table of Stats From Input Data

| Dose  | N   | Obs Mean | Obs Std Dev |
|-------|-----|----------|-------------|
| ----- | --- | -----    | -----       |
| 0     | 9   | 12.61    | 0.946       |
| 1.2   | 10  | 12.59    | 1.135       |
| 6     | 9   | 13.62    | 0.941       |
| 30    | 9   | 13.9     | 1.33        |

#### Estimated Values of Interest

| Dose  | Est Mean | Est Std | Scaled Residual |
|-------|----------|---------|-----------------|
| ----- | -----    | -----   | -----           |
| 0     | 12.47    | 1.049   | 0.3942          |
| 1.2   | 12.79    | 1.049   | -0.5972         |
| 6     | 13.5     | 1.049   | 0.3361          |
| 30    | 13.94    | 1.049   | -0.1008         |

Other models for which likelihoods are calculated:

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:             $Y_{ij} = \mu(i) + e_{ij}$   
                       $\text{Var}\{e_{ij}\} = \sigma(i)^2$

Model A3:             $Y_{ij} = \mu(i) + e_{ij}$   
                       $\text{Var}\{e_{ij}\} = \exp(\alpha + \log(\mu(i))) * \rho$

Model R:              $Y_{ij} = \mu + e(i)$   
                       $\text{Var}\{e_{ij}\} = \sigma^2$

| Likelihoods of Interest |                 |      |          |
|-------------------------|-----------------|------|----------|
| Model                   | Log(likelihood) | DF   | AIC      |
| -----                   | -----           | ---- | -----    |
| A1                      | -19.93692       | 5    | 49.87385 |
| A2                      | -19.16914       | 8    | 54.33828 |
| A3                      | -19.93692       | 5    | 49.87385 |
| R                       | -25.0757        | 2    | 54.15141 |
| 4                       | -20.25724       | 4    | 48.51447 |

Additive constant for all log-likelihoods = -34. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A2 vs. A1)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 6a: Does Model 4 fit the data? (A3 vs 4)

#### Tests of Interest

| Test    | -2*log(Likelihood Ratio) | D. F. | p-value |
|---------|--------------------------|-------|---------|
| -----   | -----                    | ----  | -----   |
| Test 1  | 11.81                    | 6     | 0.06627 |
| Test 2  | 1.536                    | 3     | 0.6741  |
| Test 3  | 1.536                    | 3     | 0.6741  |
| Test 6a | 0.6406                   | 1     | 0.4235  |

The p-value for Test 1 is greater than .05. There may not be a difference between responses and/or variances among the dose levels. Modelling the data with a dose/response curve may not be appropriate.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

Benchmark Dose Computations:

Specified Effect = 0.100000

Risk Type = Relative deviation  
Confidence Level = 0.950000  
BMD = 9.40352  
BMDL = 2.17676

## APPENDIX D. REFERENCES

- ACGIH (American Conference of Governmental Industrial Hygienists). (2016). 2016 TLVs and BEIs: Based on documentation of the threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH.  
<https://www.acgih.org/forms/store/ProductFormPublic/2016-tlvs-and-beis>
- ATSDR (Agency for Toxic Substances and Disease Registry). (2017). Minimal risk levels (MRLs). June 2017. Atlanta, GA: Agency for Toxic Substances and Disease Registry (ATSDR). Retrieved from <http://www.atsdr.cdc.gov/mrls/index.asp>
- Cal/EPA (California Environmental Protection Agency). (2011). Hot spots unit risk and cancer potency values. Appendix A. Sacramento, CA: Office of Environmental Health Hazard Assessment.  
[http://standards.nsf.org/apps/group\\_public/download.php?document\\_id=19121](http://standards.nsf.org/apps/group_public/download.php?document_id=19121)
- Cal/EPA (California Environmental Protection Agency). (2014). All OEHHA acute, 8-hour and chronic reference exposure levels (chRELs) as of June 2014. Sacramento, CA: Office of Health Hazard Assessment. <http://www.oehha.ca.gov/air/allrels.html>
- Cal/EPA (California Environmental Protection Agency). (2017a). Chemicals known to the state to cause cancer or reproductive toxicity January 27, 2017. (Proposition 65 list). Sacramento, CA: Office of Environmental Health Hazard Assessment.  
<http://oehha.ca.gov/proposition-65/proposition-65-list>
- Cal/EPA (California Environmental Protection Agency). (2017b). OEHHA toxicity criteria database [Database]: Office of Environmental Health Assessment. Retrieved from <http://www.oehha.ca.gov/tcdb/index.asp>
- Chernecky, C; Berger, B. (2013). Laboratory tests and diagnostic procedure (6th ed.). Cambridge, MA: Elsevier.
- Cholod, MS. (2001). Cyanohydrins. In Kirk-Othmer Encyclopedia of Chemical Technology. online: John Wiley & Sons.  
<http://dx.doi.org/10.1002/0471238961.0325011403081512.a01>
- DOE (U.S. Department of Energy). (2015). Table 3: Protective Action Criteria (PAC) Rev. 28 based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are listed by CASRN. December 2015. Retrieved from  
[http://www.atlintl.com/DOE/teels/teel/Revision\\_28\\_Table3.pdf](http://www.atlintl.com/DOE/teels/teel/Revision_28_Table3.pdf)
- ECHA (European Chemicals Agency). (2017). Registered substances [Database]. Helsinki, Finland. Retrieved from <https://echa.europa.eu/information-on-chemicals/registered-substances>
- FDSC HRI (Food and Drug Safety Center, Hatano Research Institute). (2016a). [2-Hydroxypropanenitrile: Bacterial reverse mutation test]. Japan existing chemical data base (JECDB). Tokyo, Japan: Ministry of Health, Labour and Welfare, Environmental Health Division (Japan). [http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF78-97-7e.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF78-97-7e.pdf)
- FDSC HRI (Food and Drug Safety Center, Hatano Research Institute). (2016b). [2-Hydroxypropanenitrile: In vitro mammalian chromosome aberration test]. Japan existing chemical data base (JECDB). Tokyo, Japan: Ministry of Health, Labour and Welfare, Environmental Health Division (Japan).  
[http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF78-97-7f.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF78-97-7f.pdf)
- Giknis, MLA; Clifford, CB. (2006). Clinical laboratory parameters for Crl:CD (SD) rats. Wilmington, MA: Charles River Laboratories.  
[http://www.criver.com/files/pdfs/rms/cd/rm\\_rm\\_r\\_clinical\\_parameters\\_cd\\_rat\\_06.aspx](http://www.criver.com/files/pdfs/rms/cd/rm_rm_r_clinical_parameters_cd_rat_06.aspx)

- Hartung, R. (1993). Cyanides and nitriles. In GD Clayton; FE Clayton (Eds.), *Pattys Industrial Hygiene and Toxicology* (4th ed., pp. 3119-3172). New York, NY: John Wiley & Sons, Inc.
- IARC (International Agency for Research on Cancer). (2015). IARC Monographs on the evaluation of carcinogenic risk to humans. Geneva, Switzerland: International Agency for Research on Cancer, WHO. <http://monographs.iarc.fr/ENG/Monographs/PDFs/index.php>
- IPCS (International Programme on Chemical Safety). (2017). INCHEM: Chemical safety information from intergovernmental organizations [Database]: World Health Organization & Canadian Centre for Occupational Health and Safety. Retrieved from <http://www.inchem.org/>
- Kaplita, PV; Smith, RP. (1986). Pathways for the bioactivation of aliphatic nitriles to free cyanide in mice. *Toxicol Appl Pharmacol* 84: 533-540. [http://dx.doi.org/10.1016/0041-008X\(86\)90258-9](http://dx.doi.org/10.1016/0041-008X(86)90258-9)
- Lewis, RJ. (2012). Lactonitrile. In *Sax's dangerous properties of industrial materials* (12th ed.). Hoboken, NJ: John Wiley & Sons, Inc. <http://dx.doi.org/10.1002/0471701343>
- Lewis, RJ, Sr; Hawley, GG. (2007). Lactonitrile. In RJ Lewis, Sr.; GG Hawley (Eds.), *Hawley's condensed chemical dictionary* (15th ed., pp. 736). Hoboken, NJ: John Wiley & Sons. <http://dx.doi.org/10.1002/9780470114735.hawley09570>
- Lide, DR. (2008). 2-hydroxypropanenitrile. CAS RN 78-97-7. In DR Lide (Ed.), *CRC handbook of chemistry and physics: A ready-reference book of chemical and physical data* (88th ed., pp. 3-300). Boca Raton, FL: CRC Press.
- Mitsubishi Chemical Safety Institute Ltd. (1992a). [2-Hydroxypropanenitrile: Acute toxicity test]. Tokyo, Japan: Ministry of Health, Labour and Welfare, Environmental Health Division (Japan). [http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF78-97-7a.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF78-97-7a.pdf)
- Mitsubishi Chemical Safety Institute Ltd. (1992b). [2-Hydroxypropanenitrile: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test]. Tokyo, Japan: Ministry of Health, Labour and Welfare, Environmental Health Division (Japan). [http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF78-97-7d.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF78-97-7d.pdf)
- Nagata, T; Fukumoto, H; Fukumoto, K; Kojima, T. (1968). A fatal case of lactonitrile poisoning. *Nihon Hoigaku Zasshi* 22: 252-256.
- NIOSH (National Institute for Occupational Safety and Health). (2016). NIOSH pocket guide to chemical hazards. Index of chemical abstracts service registry numbers (CAS No.). Atlanta, GA: Center for Disease Control and Prevention, U.S. Department of Health, Education and Welfare. <http://www.cdc.gov/niosh/npg/npgdcas.html>
- NTP (National Toxicology Program). (2014). Report on carcinogens. Thirteenth edition. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service.
- OECD (Organisation for Economic Co-operation and Development). (2004). OECD existing chemicals database. Propanenitrile, 2-hydroxy- Cas No. 78-97-7. [http://webnet.oecd.org/Hpv/UI/SIDS\\_Details.aspx?id=F92922F8-85C7-4DF1-A054-AB4C0E12DE1A](http://webnet.oecd.org/Hpv/UI/SIDS_Details.aspx?id=F92922F8-85C7-4DF1-A054-AB4C0E12DE1A)
- OSHA (Occupational Safety & Health Administration). (2006). Safety and health regulations for construction: Occupational health and environmental controls - Gases, vapors, fumes, dusts, and mists. (1926.55 App A). Washington, DC: U.S. Department of Labor. [http://www.osha.gov/pls/oshaweb/owadisp.show\\_document?p\\_table=STANDARDS&p\\_id=10629](http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10629)

- OSHA (Occupational Safety & Health Administration). (2011). Air contaminants: Occupational safety and health standards for shipyard employment, subpart Z, toxic and hazardous substances. (OSHA Standard 1915.1000). Washington, DC: U.S. Department of Labor. [https://www.osha.gov/pls/oshaweb/owadisp.show\\_document?p\\_table=STANDARDS&p\\_id=10286](https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10286)
- Smyth, HF, Jr; Carpenter, CP; Weil, CS; Pozzani, UC; Striegel, JA; Nycum, JS. (1969). Range-finding toxicity data: List VII. Am Ind Hyg Assoc J 30: 470-476. <http://dx.doi.org/10.1080/00028896909343157>
- U.S. APHC (U.S. Army Public Health Command). (2013). Environmental health risk assessment and chemical exposure guidelines for deployed military personnel. Technical guide 230, 2013 revision. Aberdeen Proving Ground, MD. <http://phc.amedd.army.mil/PHC%20Resource%20Library/TG230.pdf>
- U.S. EPA (U.S. Environmental Protection Agency). (2002). A review of the reference dose and reference concentration processes (pp. 1-192). (EPA/630/P-02/002F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www.epa.gov/osa/review-reference-dose-and-reference-concentration-processes>
- U.S. EPA (U.S. Environmental Protection Agency). (2005). Guidelines for carcinogen risk assessment [EPA Report] (pp. 1-166). (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment>
- U.S. EPA (U.S. Environmental Protection Agency). (2011a). Health effects assessment summary tables (HEAST). Washington, DC: U.S. Environmental Protection Agency, Office of Emergency and Remedial Response. <http://epa-heast.ornl.gov/heast.php>
- U.S. EPA (U.S. Environmental Protection Agency). (2011b). Recommended use of body weight 3/4 as the default method in derivation of the oral reference dose (pp. 1-50). (EPA/100/R11/0001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum, Office of the Science Advisor. <https://www.epa.gov/risk/recommended-use-body-weight-34-default-method-derivation-oral-reference-dose>
- U.S. EPA (U.S. Environmental Protection Agency). (2012a). 2012 Edition of the drinking water standards and health advisories [EPA Report]. (EPA/822/S-12/001). Washington, DC: U.S. Environmental Protection Agency, Office of Water. <http://www.epa.gov/sites/production/files/2015-09/documents/dwstandards2012.pdf>
- U.S. EPA (U.S. Environmental Protection Agency). (2012b). Benchmark dose technical guidance. In Risk Assessment Forum. (EPA/100/R-12/001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <https://www.epa.gov/risk/benchmark-dose-technical-guidance>
- U.S. EPA (U.S. Environmental Protection Agency). (2012c). PhysProp database. Estimation Programs Interface Suite for Microsoft Windows, v 4.11 [Computer Program]. Washington, DC. Retrieved from <https://www.epa.gov/tsc-screening-tools/epi-suite-tm-estimation-program-interface>
- U.S. EPA (U.S. Environmental Protection Agency). (2015a). About the TSCA chemical substance inventory. Download the non-confidential TSCA inventory [Database]. Retrieved from <http://www2.epa.gov/tsc-inventory/how-access-tsc-inventory>

- U.S. EPA (U.S. Environmental Protection Agency). (2015b). Part 355-Emergency planning and notification. Appendix A to Part 355 the list of extremely hazardous substances and their threshold planning quantities (pp. 436-447). (CFR Title 40).  
<https://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol28/pdf/CFR-2015-title40-vol28-part355.pdf>
- U.S. EPA (U.S. Environmental Protection Agency). (2017). Integrated risk information system. IRIS assessments [Database]. Washington, DC: Integrated Risk Information System. Retrieved from <http://www.epa.gov/iris/>
- UNEP (United Nations Environment Programme). (2003). 2-Hydroxypropanenitrile. In OECD Screening information data set (SIDS) for high production volume chemicals. (RISKLINE/2006060019). Nairobi, Kenya.  
<http://www.inchem.org/documents/sids/sids/HYDROXYPROPANE.pdf>
- WHO (World Health Organization). (2017). Online catalog for the Environmental Health Criteria (EHC) monographs. Geneva, Switzerland: World Health Organization (WHO).  
<http://www.who.int/ipcs/publications/ehc/en/>
- Zeiger, E; Anderson, B; Haworth, S; Lawlor, T; Mortelmans, K. (1992). Salmonella mutagenicity tests: V Results from the testing of 311 chemicals. Environ Mol Mutagen 19: 2-141. <http://dx.doi.org/10.1002/em.2850190603>
- Zimmermann, FK; Mohr, A. (1992). Formaldehyde, glyoxal, urethane, methyl carbamate, 2,3-butanedione, 2,3-hexanedione, ethyl acrylate, dibromoacetonitrile and 2-hydroxypropionitrile induce chromosome loss in *Saccharomyces cerevisiae*. Mutat Res 270: 151-166. [http://dx.doi.org/10.1016/0027-5107\(92\)90126-M](http://dx.doi.org/10.1016/0027-5107(92)90126-M)